Literature DB >> 34825221

Isolation and enrichment of mouse splenic T cells for ex vivo and in vivo T cell receptor stimulation assays.

Clémence Grosjean1, Julie Quessada1, Mathis Nozais1, Marie Loosveld1,2, Dominique Payet-Bornet1, Cyrille Mionnet1.   

Abstract

Specific antigen recognition by T cell receptor (TCR) activates TCR signaling pathway, leading to T cell proliferation and differentiation into effector and memory cells. Herein, we describe protocols for TCR stimulation assays, including procedures for the isolation and enrichment of mouse splenic T cells for ex vivo TCR stimulation with anti-CD3/CD28 antibodies, and the use of ovalbumin-OT-II mouse model for in vivo TCR stimulation. We applied this protocol to show that MYC protein is essential for T cell proliferation and differentiation. For complete details on the use and execution of this protocol, please refer to Nozais et al. (2021).
© 2021 The Author(s).

Entities:  

Keywords:  Antibody; Cell Biology; Cell culture; Cell isolation; Cell-based Assays; Flow Cytometry/Mass Cytometry; Immunology; Model Organisms

Mesh:

Substances:

Year:  2021        PMID: 34825221      PMCID: PMC8605083          DOI: 10.1016/j.xpro.2021.100961

Source DB:  PubMed          Journal:  STAR Protoc        ISSN: 2666-1667


Before you begin

In vivo assays are carried out with mouse models, thus those assays require qualified staff to perform experimental procedures on mice and to be validated by an ethical committee. The protocol below describes the specific steps for TCR stimulation of wild-type and MYC-deficient T cells with anti-CD3 and anti-CD28 antibodies or with ovalbumin. The procedure can be performed with cells expressing various types of transgenic TCR to investigate response to other kinds of antigens such as LACK (Wang et al., 2001) or Der p 1 (Dullaers et al., 2017).

Mouse models

Besides wild-type C57BL/6 mice, mouse models used in this protocol are the following. Mycflox/flox mice which allow conditional inactivation of Myc gene (Trumpp et al., 2001). Transgenic CD4-cre mice in which Cre recombinase is activated at the CD4+CD8+ (DP) stage of thymocyte differentiation (Lee et al., 2001). ROSA26-LSL-eYFP reporter mice, in those mice Cre-expressing cells express the enhanced yellow fluorescent protein (eYFP) (Srinivas et al., 2001). OT-II mice that harbor OT-II transgene encoding for a Vα2/Vβ5.1 TCR. OT-II TCR recognizes the chicken ovalbumin antigen in the context of MHC-II molecules (Barnden et al., 1998). These mice were crossed in different combination to obtain: 1) ‘Control’ that corresponds to CD4-Cre X ROSA26-LSL-eYFP mouse; 2) ‘Control OT-II’ corresponds to ‘Control’ X OT-II mouse; 3) ‘Mycdel’ corresponds to CD4-Cre X ROSA26-LSL-eYFP X Mycflox/flox mouse; and 4) ‘Mycdel OT-II’ corresponds to Mycdel X OT-II mouse. Both female and male mice were used, they were aged between 6 and 12 weeks.

Reagents preparation

Timing: 1 h Prepare the buffers and antibodies cocktails as described in the ‘materials and equipment’ section.

Key resources table

Materials and equipment

PBS1× Store at 4°C for up to one month. PBS1×/2%FBS Store at 4°C for up to one month. Complete RPMI medium Store at 4°C for up to one month. FACS buffer Store at 4°C for up to one month. Annexin V Binding Buffer Store at 4°C for up to one week. CellTrace Violet stock Make aliquots, store at −20°C up to one month and protect from light. Antibodies cocktail n°1- immunophenotyping - 20× concentrated Store at 4°C until use and protect from light. Antibodies cocktail n°2 - after enrichment – 20× concentrated Store at 4°C until use and protect from light. Antibodies cocktail n°3 – stimulation - 20× concentrated Store at 4°C until use and protect from light. Antibodies cocktail n°4 – post-graft - 20× concentrated Store at 4°C until use and protect from light. The amount of antibody mentioned in the above tables are for 5 samples containing each up to 1 × 106 cells. Antibodies cocktails are kept at 4°C in the dark and used on the day of preparation, avoid storing for more than 2 days. CRITICAL: Isoflurane gaz, xylazine and ketamine are hazardous reagents, so personal protective equipment (PPE) are needed to prevent eyes and skin damages.

Step-by-step method details

Spleen harvesting

Timing: 50 min This section describes how to obtain splenic cells (Figure 1 depicts the main steps).
Figure 1

Spleen harvesting steps

(A) Euthanize mice according to institutional guidelines. Collect spleen using scissors and tweezers. The red arrow indicates the spleen.

(B) Place spleen in a 6-well plate containing few milliliters of PBS1×/2%FBS and keep at RT.

(C) Place spleen on a 70 μm cell strainer.

(D) Dilacerate the organ with the piston of a syringe.

(E) After centrifugation, red cell pellet indicates the presence of red blood cells.

(F) Following RBC lysis buffer, the cell pellet is depleted from red cells.

(G) Hemocytometer image of cells stained with trypan blue. The red arrow indicates a dead cell while the green arrow indicates a live cell. Cells were observed with a microscope (20× magnification). To calculate cell concentration we used this formula: [Number of cells in a small grid] × 9 × dilution factor × 104 = number of cells/mL.

Euthanize mice using carbon dioxide and place them on a dissection board. Herein we used Mycdel mice (for ex vivo assay), Mycdel OT-II (for in vivo assay) mice and their Control counterparts. Sterilize the skin using 70% ethanol. Using sterile scissors, cut through the skin and the muscle layer. Visualize the spleen next to the stomach on the left side of the mouse. For euthanasia with CO2, mice are placed in a hermetically sealed box, then we use an automatic CO2 euthanasia machine (TemSega) which allows a sequence of 3 phases according to a strict and secure protocol 1) ‘induction’ phase which lasts 1 min and corresponds to a progressive saturation in CO2; 2) ‘Euthanasia’ phase which lasts 2 min (100% CO2); 3) ’Emptying’ phase which lasts 2 min and corresponds to CO2 absorption. Remove the spleen, trimming away any non-specific tissue (like fat) and place the spleen in a six-well plate containing a 3 mL of PBS1×/2%FBS in each well. Perform the following steps at room temperature (RT; 20°C–25°C) under a cell culture hood. Put a 70 μm cell strainer on top of a 50 mL conical tube. Place the organ on the cell strainer, which was previously moistened with PBS1×/2%FBS, and dilacerate the spleen with the piston of a syringe. (Add PBS1×/2%FBS to facilitate the dilaceration). Adjust the volume to 20 mL for each tube with PBS1×/2%FBS. Centrifuge (450 × g, 7 min, at RT). Discard supernatant. For all centrifugations performed in this protocol, we used shortest acceleration time/braking time. For our centrifuge (Eppendorf 5810R) this corresponds to level ACC 9/BRK 9. Add 2 mL of Red Blood Cells lysis buffer on the cell pellet. Resuspend cells by pipetting and incubate 10 min at RT. We advise to resuspend cells by gentle pipetting in order to prevent cell death, also do not exceed 10 min incubation, as it might alter cells of interest. Add 10 mL of PBS1×/2%FBS and centrifuge (450 × g, 7 min, RT). Remove supernatant and resuspend cell pellet with 10 mL of PBS1×/2%FBS. Take 5 μL of cells and mix them with 45 μL of trypan blue (previously diluted at 1:1 ratio with PBS1×). Load cell mixture into a hemocytometer. Using a microscope, count viable cells which correspond to bright cells that are not stained in blue (Figure 1G). Cells can be counted with an automated cell counter. Centrifuge conical tubes containing 10 mL of cell suspension at 450 × g (7 min, RT). Resuspend the pellet in PBS1×/2%FBS in order to be at 1 × 108 cells/mL. Spleen harvesting steps (A) Euthanize mice according to institutional guidelines. Collect spleen using scissors and tweezers. The red arrow indicates the spleen. (B) Place spleen in a 6-well plate containing few milliliters of PBS1×/2%FBS and keep at RT. (C) Place spleen on a 70 μm cell strainer. (D) Dilacerate the organ with the piston of a syringe. (E) After centrifugation, red cell pellet indicates the presence of red blood cells. (F) Following RBC lysis buffer, the cell pellet is depleted from red cells. (G) Hemocytometer image of cells stained with trypan blue. The red arrow indicates a dead cell while the green arrow indicates a live cell. Cells were observed with a microscope (20× magnification). To calculate cell concentration we used this formula: [Number of cells in a small grid] × 9 × dilution factor × 104 = number of cells/mL.

Immunophenotyping

Timing: 50 min After splenic cells harvesting, T cells are characterized by flow cytometry using specific markers to determine the percentage of CD8+, CD4+, DP or OT-II+ cells. Transfer 106 cells into a 5 mL polystyrene tube (FACS tube). Add for each sample, 5 μL of antibodies cocktail n°1 and FACS buffer up to 100 μL. Incubate for 30 min at 4°C, in the dark. Wash cells with 2 mL of PBS1×. Centrifuge cells (650 × g, 3 min, 4°C). Discard supernatant. Resuspend the cell pellet in 100 μL of FACS Buffer. Acquire cells on a flow cytometer (we used a BD Canto). Cells are not fixed so they are kept at 4°C until their acquisition which is performed as soon as possible (within 3 h maximum). Analyze files using an adapted software such as FlowJo. Antibodies cocktail is defined according to surface markers of interest.

Splenic T cells enrichment

Timing: 30 min This section describes the purification of T cells from a splenic suspension. We use mouse T cell Isolation kit (StemCellTM) which is designed to isolate T cells by negative selection and we follow the manufacturer’s instructions 10000003744-PIS_01.pdf (stemcell.com). Below (steps 22–30) is the procedure to process 5 × 107 cells (from Mycdel, Mycdel OT-II or Control mice). Transfer 5 × 107 cells into a FACS tube. Add 25 μL of Normal Rat Serum. Add 25 μL of EasySepTM Mouse T cell isolation cocktail. Incubate 10 min at RT. Vortex EasySepTM Streptavidin RapidSpheresTM for 30 s and transfer 37.5 μL into cell suspension. Incubate 2.5 min at RT. Add 2 mL PBS1×/2%FBS and pipette mix (avoid vortexing). Put the FACS tube (without cap) on a magnet and wait 2.5 min at RT. Transfer cell suspension into a new 15 mL conical collection tube by inverting magnet/FACS tube in a single continuous motion. CRITICAL: It’s very important to make this movement properly and without shaking to prevent beads from coming loose. Count cells as described in steps 11 and 12. To check the quality of the purification, take an aliquot (around 50 μL of cell suspension) and stain cells with 5 μL of antibodies cocktail n°2. Then, proceed to steps 17–21 described above. An example of FACS analysis of T cells purification is shown in Figure 2.
Figure 2

T cells enrichment

FACS plot showing the expression of CD4 and CD8. Percentages of cells in depicted gates are indicated.

(A) Before T cells enrichment.

(B) After T cells enrichment.

Centrifuge cells (450 × g, 7 min, RT). Aspirate supernatant. Resuspend cell pellet at 2 × 107 cells/mL in PBS1×. FACS analysis step is important to assess the efficiency and the quality of T cell enrichment. T cells enrichment FACS plot showing the expression of CD4 and CD8. Percentages of cells in depicted gates are indicated. (A) Before T cells enrichment. (B) After T cells enrichment.

Cell trace violet staining

Timing: 25 min This step describes cell staining with a carboxyfluorescein succinimidyl ester (CFSE)-based reagent in order to follow cell proliferation. Here we use CellTraceTM Violet (CTV), yet other types of CFSE-based reagents are commercially available. Dilute CTV stock solution (5 mM) at 1:1000 with PBS1× and protect from light. In a microcentrifuge tube, add 20 μL diluted CTV (5 μM) to 3 × 106 cells in 1 mL PBS1×. Mix well by gentle pipetting. Incubate at 37°C for 15 min (in the dark). Wash cells twice with 500 μL of cold PBS1×. Spin cells (700 × g, 5 min, 4°C). Resuspend cell pellet in complete RPMI (for ex vivo assays, step 39) or PBS1× (for in vivo assays, step 50) and store at 4°C in the dark until use. The samples can be stored at 4°C until use, but usually cells are used within 3 h in order to prevent cell death.

Ex vivo T cell receptor stimulation

Timing: 3 days In the following section T cells are stimulated by anti-CD3 and anti-CD28 antibodies and analyzed by flow cytometry 24H and 72H post-stimulation. Resuspend cells in complete RPMI at a cell concentration of 3 × 106 cells/mL In a 48-well plate, dispatch 106 cells of each sample in 2 wells: Well #1: ‘Not stimulated’. Well #2: ‘Stimulated CD3/CD28’: add 10 μL Dynabeads Mouse T-activator CD3/CD28. Addition of a control well. In a well #3 ‘PMA/ionomycin’: add Phorbol myristate acetate (PMA) and ionomycin at a final concentration of 0.1 μg/mL and 2 μg/mL respectively. Instead of using Dynabeads for stimulation, it is possible to pre-coat the plate with anti- CD3 antibodies and then add cell suspension together with anti-CD28 antibodies. Incubate at 37°C in a 5% CO2 incubator. At 24H, resuspend cells by gentle pipetting and take 100 μL cells in FACS tube. Add 1 mL PBS1× in each sample. For stimulated cells, put the tube on a magnet to remove Dynabeads. Wait 2 min and collect the supernatant into another FACS tube. For all samples, centrifuge cells (700 × g, 5 min, 4°C). Discard supernatant. Add 5 μL of antibodies cocktail n°3 and FACS Buffer up to 100 μL for each sample. Incubate for 30 min at 4°C, in the dark. Wash cells by adding 2 mL Annexin-V binding buffer 1×. Centrifuge cells (650 × g, 3 min, 4°C) and discard the supernatant. Resuspend cell pellet in 100 μL of Annexin-V binding buffer 1× and add 1 μL of Annexin-V APC. Acquire cells on a flow cytometer and analyze data using FlowJo software. At 72H, repeat steps 42–48.

In vivo T cell receptor stimulation

Timing: 7 days Herein, we performed in vivo stimulation assays using OT-II mouse model. This model generates some CD4 T cells expressing OT-II TCR which recognizes chicken ovalbumin antigen (Barnden et al., 1998). The major steps are the following: at day 0, splenic T cells (from OT-II MYC-deficient or MYC-proficient mice) are harvested and engrafted in C57BL/6 recipient mice. After two days, T cells are stimulated through injection of ovalbumin (Day 2) and few (usually ranging from 3 to 5) days later, mice are euthanized for analysis (Day 7). Resuspend CTV-labelled cells (from step 38 above) at 10 × 106 cells/mL in PBS1× at RT and protect from light. Sedate C57BL/6 recipient mice using isoflurane with a flow rate of 4 L/min for 3 min. Mice sedation can be performed by an intraperitoneal injection of xylazine/ketamine anesthetic. 100 μL of cells are i.v. injected (retro orbital injection) using an insulin syringe (or 1 mL syringe with 30 gauge needle). Tail vein injection can be applied. Place grafted mice under a heating lamp until they wake up, and then put them back in their cage. Allow mice to recover (here we set 2 days for the recovery time). After 2 days, anesthetize grafted mice as described in step 51. Perform a subcutaneous injection in the ear of 100 μg of ovalbumin in the presence of complete Freund’s adjuvant (maximum volume of injection: 100 μL) (Figure 3).
Figure 3

Ovalbumin/CFA injection

(A) Preparation of ovalbumin-CFA mixture. Two syringes containing ovalbumin and complete Freund’s adjuvant are linked together by a connector. The two solutions are mixed by pressing several times the plunger of the two syringes.

(B) The ear of the sedated mouse is immobilized with a tape.

(C) Subcutaneous injection to the ear. Place the needle of the syringe subcutaneously.

(D) Inject ovalbumin-CFA mixture by pushing the plunger of the syringe. The blue arrow shows swelling due to correct injection.

Ovalbumin/CFA injection (A) Preparation of ovalbumin-CFA mixture. Two syringes containing ovalbumin and complete Freund’s adjuvant are linked together by a connector. The two solutions are mixed by pressing several times the plunger of the two syringes. (B) The ear of the sedated mouse is immobilized with a tape. (C) Subcutaneous injection to the ear. Place the needle of the syringe subcutaneously. (D) Inject ovalbumin-CFA mixture by pushing the plunger of the syringe. The blue arrow shows swelling due to correct injection. Place injected mice under a heating lamp until they wake up. 3–5 days post-immunization, euthanize grafted mice (as described in step 1) for analysis. Collect the cervical lymph nodes, trimming away any non-specific tissue (like fat) and place the lymph nodes in PBS1×/2%FBS at RT. Put a 70 μm cell strainer on a 50 mL conical tube. Place lymph nodes on the cell strainer, which was previously moistened with PBS1×/2%FBS, and dilacerate with the piston of a syringe. Adjust the volume to 10 mL with PBS1×/2%FBS. Centrifuge cells (450 × g, 7 min, RT). Discard supernatant. Resuspend cell pellet with 5 mL of PBS1×/2%FBS. Count cells as described in steps 11 and 12. Transfer 106 cells into a FACS tube. Add 5 μL of antibodies cocktail n°4 and FACS Buffer up to 100 μL for each sample. Incubate for 30 min at 4°C, in the dark. Add 2 mL PBS1× and centrifuge (650 × g, 3 min, 4°C). Discard supernatant. Resuspend cell pellet in 100 μL of FACS buffer. Acquire cells on a flow cytometer and analyze files using FlowJo software. Our mouse models bred on C57BL/6 background harbor ROSA26-LSL-eYFP tracking system, thus we can easily distinguish cells of interest from host wild type C57BL/6 cells. As an alternative to ROSA26-LSL-eYFP, two distinct strains of C57BL/6 mice can be used to differentiate host cells from injected cells: typically CD45.1 or CD45.2 C57BL/6 mice strains.

Expected outcomes

This protocol aims to investigate T cell response upon TCR stimulation. With physiological T cells, ex vivo stimulation with anti-CD3/CD8 antibodies, induces cell surface expression of activation-marker genes, such as CD69, and also cell growth and a burst of proliferation. Those responses to TCR stimulation can be monitored by flow cytometry (Figure 4). Typically, cell proliferation is assessed using CFSE-based reagent like CTV (Figure 4D). Then, impact on T cell response can be investigated according to different factors. Herein we analyzed the impact of Myc inactivation and we found that MYC-deficient T cells do not proliferate despite CD69 expression (Figure 4). These ex vivo results can be further validated by in vivo assays in which T cells are stimulated with a specific antigen. We used ovalbumin to activate T cells that harbor OT-II TCR. As expected, physiological OT-II+ T cells proliferate upon ovalbumin injection whereas MYC-deficient OT-II cells do not expand (Figure 5). Moreover, in vivo analysis allows the investigation of T helper (Th) cell polarization. Herein, we injected ovalbumin with complete Freund’s adjuvant, that favors Th1/Th17 polarization. However, alternative adjuvants such as Alum (aluminum hydroxide) support Th2 polarization (Vasilakos et al., 2000).
Figure 4

Ex vivo stimulation assays

(A) Gating strategy to select eYFP+ cells population.

(B) Analysis of CD69 surface expression 24H post-stimulation was performed using eYFP+ cells from Control and Mycdel mice.

(C) SSC/FSC analysis of eYFP+ cells at 24H and 72H post-stimulation.

(D) Analysis of proliferation of eYFP+ cell performed at 24H and 72H post-stimulation. Decrease of CTV staining indicates cell proliferation.

(B and D) Red histograms correspond to unstimulated cells and blue histograms to anti-CD3/CD28 stimulated cells.

Figure 5

In vivo stimulation assays

(A) T cells from Control OT-II (top panels) and Mycdel OT-II (bottom panels) spleens were purified and labeled with CTV. FACS showing CD4 and CD8 expression (left panels). CD4+ gate was further analyzed for OT-II and eYFP expression (right panels). The histogram displays CTV staining of OT-II+eYFP+ cells from Control OT-II (red) and Mycdel OT-II (blue).

(B) FACS analysis of lymph nodes from mice transplanted with Control OT-II and Mycdel OT-II cells 3 and 5 days post-ovalbumin injection. Top panels: CD4 and CD8 expression. Bottom panels: OT-II and eYFP expression in CD4+ cells. The histograms display CTV staining of OT-II+eYFP+ cells from Control OT-II (red) and Mycdel OT-II (blue).

Ex vivo stimulation assays (A) Gating strategy to select eYFP+ cells population. (B) Analysis of CD69 surface expression 24H post-stimulation was performed using eYFP+ cells from Control and Mycdel mice. (C) SSC/FSC analysis of eYFP+ cells at 24H and 72H post-stimulation. (D) Analysis of proliferation of eYFP+ cell performed at 24H and 72H post-stimulation. Decrease of CTV staining indicates cell proliferation. (B and D) Red histograms correspond to unstimulated cells and blue histograms to anti-CD3/CD28 stimulated cells. In vivo stimulation assays (A) T cells from Control OT-II (top panels) and Mycdel OT-II (bottom panels) spleens were purified and labeled with CTV. FACS showing CD4 and CD8 expression (left panels). CD4+ gate was further analyzed for OT-II and eYFP expression (right panels). The histogram displays CTV staining of OT-II+eYFP+ cells from Control OT-II (red) and Mycdel OT-II (blue). (B) FACS analysis of lymph nodes from mice transplanted with Control OT-II and Mycdel OT-II cells 3 and 5 days post-ovalbumin injection. Top panels: CD4 and CD8 expression. Bottom panels: OT-II and eYFP expression in CD4+ cells. The histograms display CTV staining of OT-II+eYFP+ cells from Control OT-II (red) and Mycdel OT-II (blue).

Limitations

In vivo assays require an animal facility, competent staff to take care of mouse models and to perform experimental procedures on mice. These assays also depend on the availability of TCR transgenic mice. Herein, we used OT-II mice that can be stimulated by ovalbumin, if the mice possess another type of transgenic TCR, the stimulation should be performed with the corresponding antigen. We did not identify any limitation for ex vivo assays. By itself, these assays do not require any specific expertise and can be easily performed by beginners. Moreover, besides basic equipment needed for molecular/cellular biology (such as centrifuge, microscope, flow cytometer), ex vivo assays do not necessitate any particular material.

Troubleshooting

Problem 1

CTV labelling is insufficient (at 24H, a mean fluorescence intensity below 104 is considered as insufficient) (step 33).

Potential solution

Only use freshly diluted solution of CTV. Increase the final concentration of CTV or test several CTV concentrations to obtain the optimal labeling of your cells.

Problem 2

Insufficient T cells enrichment (fall short of 85%) (step 30 b). The problem may result from a counting error. Underestimating the cell count can impact the efficiency of purification. You may increase by 10% the recommended amount of antibody cocktail and beads.

Resource availability

Lead contact

Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact. Dominique Payet Bornet (payet@ciml.univ-mrs.fr).

Materials availability

This study did not generate new unique reagents.
REAGENT or RESOURCESOURCEIDENTIFIER
Antibodies

CD3 APC Cy7 (1:400)BD PharmingenCat#: 560590, RRID: AB_1727461
CD4 V450 (1:500)BD PharmingenCat#: 560468, RRID: AB_1645271
CD4 APC (1:500)BD PharmingenCat#: 553051, RRID: AB_398528
CD4 PerCP Cy 5.5 (1:400)BD PharmingenCat#: 561115, RRID: AB_10563934
CD8a PerCP Cy5.5 (1:400)BD PharmingenCat#: 561109, RRID: AB_10563417
CD8a PE Cy7 (1:400)BD PharmingenCat#: 552877, RRID: AB_394506
CD25 PE (1:800)BD PharmingenCat#: 561065, RRID: AB_10563211
CD44 APC Cy7 (1:400)BD PharmingenCat#: 560568, RRID: AB_1727481
CD62L APC (1:500)BD PharmingenCat#: 561919, RRID: AB_1645257
CD69 PerCP Cy5.5 (1:400)BD PharmingenCat#: 561931, RRID: AB_10892815
TCR Vβ5 PE (1:400)BD PharmingenCat#: 553190, RRID: AB_394698
TCR Vα2 APC (1:400)eBioscienceCat#: 17-5812-80, RRID: AB_469460

Chemicals, peptides, and recombinant proteins

Dynabeads® Mouse T-Activator CD3/CD28Life TechnologiesCat#: 11456D
Annexin V-APCBD PharmingenCat#: 550474
Complete Freund’s adjuvantSigma-AldrichCat#: F5881
EndoFit OvalbuminInvivogenCat#: vac-pova
RPMI 1640Life TechnologiesCat#: 21875-034
Dulbecco’s Phosphate Buffered Saline 10×Life TechnologiesCat#: 14200-067
RBC lysis bufferLife TechnologiesCat#: 00-4333-57
Fetal Bovine SerumLife TechnologiesCat#: 10270-106
Annexin V Binding BufferBD PharmingenCat#: 51-66121E
β-mercaptoethanolLife TechnologiesCat#: 31350-010
GlutaMaxLife TechnologiesCat#: 25030-024
Sodium pyruvateLife TechnologiesCat#: 11360-039
Penicillin-StreptomycinLife TechnologiesCat#: 15140122
Ethylenediaminetetraacetic acidLife technologiesCat#: 15576-028
Trypan Blue solutionSigma-AldrichCat#: T8154
IonomycinLife technologiesCat#: I24222
Phorbol myristate acetateSigma-AldrichCat#: P8139

Critical commercial assays

EasySepTM Mouse T cell isolation kitLife TechnologiesCat#: 19851
CellTrace VioletInvitrogenCat#: C34557

Experimental models: Organisms/strains

Mycflox/flox miceAndreas Trumpp (DKFZ)Trumpp A. Nature. 414, 768-73 (2001).
CD4-Cre miceEuropean Mouse Mutant ArchiveEM: 01139
OT-II miceBarnden MJ. Immunol Cell Biol.76, 34–40 (1998)MGI: 3046083
ROSA26-LSL-eYFP reporter miceThe Jackson LaboratoryMGI: 2449038
C57BL/6 miceThe Jackson LaboratoryMGI:2159769

Software and algorithms

FlowJo version 10FlowJohttps://www.flowjo.com/
Diva version 8.0.1BD Bioscienceshttps://www.bdbiosciences.com/

Other

6-well plateFalconCat#: 353046
48-well plateFalconCat#: 353078
5 mL polystyrene tubesFalconCat#: 352054
15 mL tubesSarstedtCat#: 62.554.502
50 mL tubesSarstedtCat#: 62.547.254
70 μm cell strainerSarstedtCat#: 83.3945.070
1 mL syringeTerumoCat#: SS+01H1
2.5 mL syringeTerumoCat#: SS-02SE1
30G needleFisher ScientificCat#: 15391557
EasySep MagnetStemCellCat#: 18000
HemocytometerKOVA InternationalCat#: 87144F
MicroscopeNikon EclipseTS100
CentrifugeEppendorfCat#: G5810R
MicrocentrifugeEppendorfCat#: G5415R
Flow cytometerBD BiosciencesFACS Canto II
Isofluorane (Vetflurane)Centravetn/a
Xylazine (Rompun 2%)Centravetn/a
Ketamine (Imalgen 1000)Centravetn/a

PBS1×

ReagentFinal concentrationAmount
Dulbecco′s Phosphate Buffered Saline (DPBS) 10×1 X100 mL
dH2On/aUp to 1 L
Totaln/a1 L

Store at 4°C for up to one month.

PBS1×/2%FBS

ReagentFinal concentrationAmount
Fetal Bovine Serum2%8 mL
PBS1×1 XUp to 400 mL
Totaln/a400 mL

Store at 4°C for up to one month.

Complete RPMI medium

ReagentFinal concentrationAmount
β-mercaptoethanol50 μM500 μL
Fetal Bovine Serum10%50 mL
GlutaMax1 X5 mL
Sodium pyruvate1 X5 mL
Penicillin-Streptomycin1 X5 mL
RPMI 1640n/aUp to 500 mL
Totaln/a500 mL

Store at 4°C for up to one month.

FACS buffer

ReagentFinal concentrationAmount
Fetal Bovine Serum1%1 mL
Ethylenediaminetetraacetic acid2 mM200 μL
PBS1×1 XUp to 50 mL
Totaln/a50 mL

Store at 4°C for up to one month.

Annexin V Binding Buffer

ReagentFinal concentrationAmount
Annexin V Binding Buffer1 X1 mL
dH2On/aUp to 10 mL
Totaln/a10 mL

Store at 4°C for up to one week.

CellTrace Violet stock

ReagentFinal concentrationAmount
CellTrace Violet kit (CTV)5 mM1 vial
DMSOn/a20 μL
Totaln/a20 μL

Make aliquots, store at −20°C up to one month and protect from light.

Antibodies cocktail n°1- immunophenotyping - 20× concentrated

ReagentAmountDilution in antibodies cocktailWorking dilution (in the final cell suspension)
CD4 V4501 μL1:251:500
CD8 PerCP Cy5.51.25 μL1:201:400
CD3 APC Cy71.25 μL1:201:400
Vα2 APC1.25 μL1:201:400
Vβ5 PE1.25 μL1:201:400
FACS BufferUp to 25 μLn/an/a
Total25 μL

Store at 4°C until use and protect from light.

Antibodies cocktail n°2 - after enrichment – 20× concentrated

ReagentAmountDilution in antibodies cocktailWorking dilution (in the final cell suspension)
CD4 APC1 μL1:251:500
CD8 PerCP Cy5.51.25 μL1:201:400
CD3 APC Cy71.25 μL1:201:400
Vβ5 PE1.25 μL1:201:400
FACS BufferUp to 25 μLn/an/a
Total25 μL

Store at 4°C until use and protect from light.

Antibodies cocktail n°3 – stimulation - 20× concentrated

ReagentAmountDilution in antibodies cocktailWorking dilution (in the final cell suspension)
CD25 PE0.6 μL1:401:800
CD69 PerCP Cy5.51.25 μL1:201:400
CD44 APC Cy71.25 μL1:201:400
FACS BufferUp to 25 μLn/an/a
Total25 μL

Store at 4°C until use and protect from light.

Antibodies cocktail n°4 – post-graft - 20× concentrated

ReagentAmountDilution in antibodies cocktailWorking dilution (in the final cell suspension)
CD4 PerCP Cy5.51.25 μL1:201:400
CD8 PE Cy71.25 μL1:201:400
CD44 APC Cy71.25 μL1:201:400
CD62L APC1 μL1:251:500
Vβ5 PE1.25 μL1:201:400
FACS BufferUp to 25 μLn/an/a
Total25 μL

Store at 4°C until use and protect from light.

  8 in total

1.  A critical role for Dnmt1 and DNA methylation in T cell development, function, and survival.

Authors:  P P Lee; D R Fitzpatrick; C Beard; H K Jessup; S Lehar; K W Makar; M Pérez-Melgosa; M T Sweetser; M S Schlissel; S Nguyen; S R Cherry; J H Tsai; S M Tucker; W M Weaver; A Kelso; R Jaenisch; C B Wilson
Journal:  Immunity       Date:  2001-11       Impact factor: 31.745

2.  CD4 promotes breadth in the TCR repertoire.

Authors:  Q Wang; L Malherbe; D Zhang; K Zingler; N Glaichenhaus; N Killeen
Journal:  J Immunol       Date:  2001-10-15       Impact factor: 5.422

3.  Adjuvant activities of immune response modifier R-848: comparison with CpG ODN.

Authors:  J P Vasilakos; R M Smith; S J Gibson; J M Lindh; L K Pederson; M J Reiter; M H Smith; M A Tomai
Journal:  Cell Immunol       Date:  2000-08-25       Impact factor: 4.868

4.  Defective TCR expression in transgenic mice constructed using cDNA-based alpha- and beta-chain genes under the control of heterologous regulatory elements.

Authors:  M J Barnden; J Allison; W R Heath; F R Carbone
Journal:  Immunol Cell Biol       Date:  1998-02       Impact factor: 5.126

5.  House dust mite-driven asthma and allergen-specific T cells depend on B cells when the amount of inhaled allergen is limiting.

Authors:  Melissa Dullaers; Martijn J Schuijs; Monique Willart; Kaat Fierens; Justine Van Moorleghem; Hamida Hammad; Bart N Lambrecht
Journal:  J Allergy Clin Immunol       Date:  2016-10-13       Impact factor: 10.793

6.  c-Myc regulates mammalian body size by controlling cell number but not cell size.

Authors:  A Trumpp; Y Refaeli; T Oskarsson; S Gasser; M Murphy; G R Martin; J M Bishop
Journal:  Nature       Date:  2001-12-13       Impact factor: 49.962

7.  Cre reporter strains produced by targeted insertion of EYFP and ECFP into the ROSA26 locus.

Authors:  S Srinivas; T Watanabe; C S Lin; C M William; Y Tanabe; T M Jessell; F Costantini
Journal:  BMC Dev Biol       Date:  2001-03-27       Impact factor: 1.978

8.  MYC deficiency impairs the development of effector/memory T lymphocytes.

Authors:  Mathis Nozais; Marie Loosveld; Saran Pankaew; Clémence Grosjean; Noémie Gentil; Julie Quessada; Bertrand Nadel; Cyrille Mionnet; Delphine Potier; Dominique Payet-Bornet
Journal:  iScience       Date:  2021-06-19
  8 in total
  3 in total

1.  Single-cell RNA-sequencing identifies anti-cancer immune phenotypes in the early lung metastatic niche during breast cancer.

Authors:  Sophia M Orbach; Michael D Brooks; Yining Zhang; Scott E Campit; Grace G Bushnell; Joseph T Decker; Ryan J Rebernick; Sriram Chandrasekaran; Max S Wicha; Jacqueline S Jeruss; Lonnie D Shea
Journal:  Clin Exp Metastasis       Date:  2022-08-24       Impact factor: 4.510

2.  Isolation and culture of pure adult mouse microglia and astrocytes for in vitro characterization and analyses.

Authors:  Mark T Milner; Grace Mep Lawrence; Caroline L Holley; Liviu-Gabriel Bodea; Jürgen Götz; Sabrina S Burgener; Kate Schroder
Journal:  STAR Protoc       Date:  2022-04-11

3.  A protocol to evaluate immunoglobulin deposits in mouse glomeruli.

Authors:  Sonia B Nambadan; Maurice Stanley; Yaoyuan Zhang; Vicki Athanasopoulos; Simon H Jiang
Journal:  STAR Protoc       Date:  2022-05-11
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.